Canada: Pharmaceutical patents in Canada – regulatory changes

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Canada: Pharmaceutical patents in Canada – regulatory changes

Following the signing of the Comprehensive Economic and Trade Agreement (CETA) with the European Union, the Government of Canada has amended Canada's pharmaceutical drug linkage regulations, the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations), which link the drug regulatory approval system to the patent system. The PMNOC Regulations are comparable to the Hatch-Waxman Act in the United States.

In Canada, to gain authorisation for a new innovative drug, an innovator submits to Health Canada a New Drug Submission (NDS) setting out data establishing the safety and efficacy of the drug. Upon regulatory approval by Health Canada, a Notice of Compliance (NOC) is issued authorising the drug for sale. Relevant patents pertaining to the innovative drug are eligible to be listed on a public Patent Register and are entitled to protection under the PMNOC Regulations.

A generic manufacturer that files an Abbreviated New Drug Submission ("ANDS") with Health Canada seeking approval of a generic version of an innovative drug must successfully address each relevant patent listed on the Patent Register before an NOC will be granted for the generic version. The generic manufacturer may, for example, serve a Notice of Allegation (NOA) alleging non-infringement and/or invalidity of listed patents, triggering proceedings under the PMNOC Regulations.

The amended PMNOC Regulations apply to all submissions for which an NOA is served on or after September 21 2017. At a high level, the previously existing summary proceedings have now been replaced by a full right of action, with accompanying procedural guarantees and discovery obligations, ending dual litigation. The amendments alter the regime that has governed pharmaceutical patent litigation in Canada for nearly 25 years.

The PMNOC Regulations previously provided a summary procedure in which allegations of patent infringement and invalidity could be decided. Parties, however, remained free to challenge or assert the same patent as between the same parties and for the same drug in a separate action under the Canadian Patent Act. Dual litigation was thus possible for the same patent and drug, leading to potentially inconsistent results. The summary proceedings, heard on a written record, have now been replaced with a full right of action involving up-front disclosure and discovery, and concluding in a trial.

Under the amended PMNOC Regulations, the only opportunity for an innovator to sue on patents addressed in an NOA is within 45 days of receipt of the NOA. No other action may be brought for infringement of any patent that is the subject of the NOA, unless the innovator did not have a reasonable basis for bringing the action at the time. There is also now the ability for an innovator to sue on patents beyond those listed on the Patent Register, on the basis of information received in the NOA.

Additional notable developments in the pharmaceutical patent-regulatory interface flowing from CETA include the introduction of Certificates of Supplementary Protection (CSPs), which have been implemented to compensate innovators for lost patent term due to regulatory delays.

Tamara O’Connell


Smart & Biggar/ Fetherstonhaugh55 Metcalfe Street Suite 900PO Box 2999 Station DOttawa ON  K1P 5Y6Tel: 613 232 2486Fax: 613 232 8440 ottawa@smart-biggar.cawww.smart-biggar.ca

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article